ST. LOUIS — Consumers are suing the makers of a medication, citing alleged breach of implied warranty.
Cheryl Carver, as a representative for Elisie Mullins, Frank Clarke, Cashene Cain, Ernest Campbell, et. al. filed a complaint Sept. 8 in the St. Louis 22nd Judicial Circuit Court against Boehringers Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GMBH; Boehringer Ingelheim Roxane Inc.; Boehringer Ingelheim Pharma GMBH & Co. KG; and Bidachem S.P.A., alleging the defendants failed to warn physicians and consumers of the risks associated with using Pradaxa.
According to the complaint, consumers allege that in 2010, the Food and Drug Administration approved Pradaxa as an oral anticoagulant to reduce the risk of stroke related to atrial fibrillation. The plaintiffs claim the product has harmful effects that put patients at an increased risk for developing life-threatening bleeding and that such risks were never disclosed to physicians and patients. As a result, the plaintiffs say they have suffered injuries that led to untimely death to some patients.
The plaintiffs hold the defendants responsible because they allegedly failed to provide appropriate warnings and instructions about the dangers posed by Pradaxa, failed to conduct adequate safety and efficacy studies before marketing the product and failed to design a product that would not cause personal injuries or death.
The plaintiffs request a trial by jury and seek judgment for general, compensatory and punitive damages, costs of action and further relief the court deems appropriate. They are represented by John J. Driscoll of The Driscoll Firm PC in St. Louis.
St. Louis 22nd Judicial Circuit Court case number 1722-CC11300